title: Effect of amlodipine on vascular responses after coronary stenting compared with an angiotensin-converting enzyme inhibitor.
abstract: BACKGROUND
  Prevention of restenosis after coronary stenting is clinically important. We compared amlodipine and quinapril to determine which is more effective in preventing restenosis after stenting.
  
  
  RESULTS
  Immediately after successful coronary stenting of 101 lesions in 63 consecutive patients, the patients were randomly divided into 2 groups: 32 patients with 48 lesions were administered amlodipine 5 mg/day (group A), and 31 patients with 53 lesions were administered quinapril 10 mg/day (group Q). Lesions were assessed by quantitative coronary angiography (QCA) before and immediately after stenting and in the follow-up phase. Intravascular ultrasound (IVUS) could only be performed on 20 lesions in group A and 16 lesions in group Q throughout the follow-up period. We analyzed each lesion at 5 sites. In the follow-up phase, the minimal lumen diameter in group A was significantly larger than that in group Q (1.88 +/- 0.64 mm vs 1.52 +/- 0.53 mm, p<0.01). In the follow-up phase, the neointimal area (stent area-lumen area) in group A was significantly smaller than that in group Q (1.9 +/- 0.5 mm2 vs 2.7 +/- 0.8 mm2 at the middle portion of stent, p<0.01).
  
  
  CONCLUSIONS
  These QCA and IVUS findings suggest that amlodipine has beneficial effects in inhibiting neointimal hyperplasia in stented lesions compared with quinapril.
authors.affiliation: Division of Cardiology, Jikei University School of Medicine, Tokyo, Japan. t.yama@jikei.ac.jp
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Yamazaki
authors.forename: Ikuo
authors.initials: I
authors.lastname: Taniguchi
authors.forename: Takashi
authors.initials: T
authors.lastname: Kurusu
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Shimazu
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Hashizume
authors.forename: Kazutoshi
authors.initials: K
authors.lastname: Takikawa
authors.forename: Masao
authors.initials: M
authors.lastname: Kuwata
authors.forename: Tatsuyuki
authors.initials: T
authors.lastname: Onodera
authors.forename: Makoto
authors.initials: M
authors.lastname: Yoshikawa
authors.forename: Seibu
authors.initials: S
authors.lastname: Mochizuki
mesh_terms: D000368:Aged; D017311:Amlodipine / Q000494:pharmacology / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D017023:Coronary Angiography; D003327:Coronary Disease / Q000188:drug therapy / Q000628:therapy*; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000517:prevention & control*; D003331:Coronary Vessels / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D000077583:Quinapril; D015607:Stents; D044005:Tetrahydroisoquinolines / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D017539:Tunica Intima / Q000000981:diagnostic imaging / Q000187:drug effects / Q000473:pathology; D018084:Ultrasonography, Interventional; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D044005:Tetrahydroisoquinolines; D014665:Vasodilator Agents; D017311:Amlodipine; D000077583:Quinapril